Home

Schizophrenia

Read time: 4 min

Congress highlights

Pros and cons of persisting with antipsychotic treatment: assessing the evidence

Guidelines recommend that people with first-episode psychosis should where possible be maintained...

Read time: 5 min

Congress highlights

Recovery – from schizophrenia symptoms to well-being

Recovery in an important focus in the treatment and management of schizophrenia but what exactly is...

Read time: 4 min

Congress highlights

If one antipsychotic is good, why aren’t two better? Polypharmacy debated

Increased risk of side effects, reduced compliance, lack of rationale and, above all, no evidence...

Depression, Schizophrenia

Read time: 4 min

Congress highlights

E-mental health is revolutionizing and reshaping mental health practice worldwide

E-mental health is revolutionizing and reshaping mental health care practice worldwide. This...

Read time: 4 min

Congress highlights

Mortality excess in schizophrenia: can we close the gap?

People with first-episode psychosis who had no antipsychotic medication treatment had a five-year...

Read time: 3 min

Congress highlights

Networking - a brilliant take off or a flight of fancy?

You would think that the behaviour of a flock of starlings would have little to do with mental...

Read time: 3 min

Bouncing back - Resilience in schizophrenia

Can we improve resilience in patients with schizophrenia to help recovery? Resilience is...

Read time: 4 min

GABA dysfunction – preclinical and clinical imaging perspectives in schizophrenia

The association between abnormal interneuronal function and neuropsychiatric conditions is...

Read time: 3 min

Right treatment at right time: Improving outcomes in first episode psychosis

Integrating evidence-based psychosocial and pharmacological treatments significantly improves the...

Bipolar, Schizophrenia

Read time: 4 min

Exploring brain connectivity in schizophrenia

There has been an explosion of interest in research on brain connectivity, across disorders in...

Read time: 2 min

Value of Treatment: European Brain Council publishes landmark report

Greater clinical benefit for patients and gains in cost-effectiveness for society -- both can be...

Depression, Schizophrenia

Read time: 2 min

Congress highlights

Sexual side-effects – let’s talk!

Sexual side-effects, sometimes experienced by patients during treatment, are not only debilitating...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country